Identification

Name
Sucralfate
Accession Number
DB00364  (APRD01238)
Type
Small Molecule
Groups
Approved
Description

A basic aluminum complex of sulfated sucrose. [PubChem]

Structure
Thumb
Synonyms
  • Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
  • Sucralfat
  • Sucralfate
  • Sucralfato
  • Sucralfatum
External IDs
CGA-6J / OS 202
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarafateTablet1 g/1OralAllergan1981-10-30Not applicableUs
CarafateSuspension1 g/10mLOralAtlantic Biologicals Corps.1993-12-16Not applicableUs
CarafateSuspension1 g/10mLOralAllergan1993-12-16Not applicableUs
CarafateSuspension1 g/10mLOralPhysicians Total Care, Inc.1996-03-12Not applicableUs
Dom-sucralfateTablet1000 mgOralDominion Pharmacal1999-09-152016-10-25Canada
Nu-sucralfate - Tab 1gmTablet1 gOralNu Pharm Inc1994-12-312012-09-04Canada
PMS-sucralfateTablet1000 mgOralPharmascience Inc1999-02-23Not applicableCanada
SucralfateTablet1 g/1OralActavis Pharma Company1996-11-012020-03-31Us
SucralfateSuspension1 g/10mLOralVista Pharm, Inc.2012-08-16Not applicableUs
SucralfateTablet1 g/1OralAphena Pharma Solutions Tennessee, Inc.1996-11-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sucralfate - Tab 1gTablet1 gOralApotex Corporation1994-12-31Not applicableCanada
SucralfateTablet1 g/1OralCardinal Health2010-01-082016-03-11Us
SucralfateTablet1 g/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-08Not applicableUs
SucralfateTablet1 g/1OralMc Kesson Contract Packaging2011-11-29Not applicableUs
SucralfateTablet1 g/1OralNostrum Laboratories, Inc.2009-07-01Not applicableUs
SucralfateTablet1 g/1OralLake Erie Medical Dba Quality Care Produts Llc1996-11-11Not applicableUs
SucralfateTablet1 g/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation1996-11-11Not applicableUs
SucralfateTablet1 g/1OralMesource Pharmaceuticals1996-11-11Not applicableUs
SucralfateTablet1 g/1OralA S Medication Solutions1996-11-11Not applicableUs
SucralfateTablet1 g/1OralAmerincan Health Packaging2012-03-012016-10-31Us
International/Other Brands
Antepsin (Orion) / Sucramal (Menarini) / Sucraxol (Medifarma) / Ulcogant (Merck)
Categories
UNII
XX73205DH5
CAS number
54182-58-0
Weight
Average: 1448.682
Monoisotopic: 1447.588619666
Chemical Formula
C11H28Al8O51S8
InChI Key
MNQYNQBOVCBZIQ-JQOFMKNESA-A
InChI
InChI=1S/C11H20O35S8.8Al.16H2O/c12-47(13,14)36-1-3-4(41-49(18,19)20)5(42-50(21,22)23)6(43-51(24,25)26)9(38-3)39-11(2-37-48(15,16)17)8(45-53(30,31)32)7(44-52(27,28)29)10(40-11)46-54(33,34)35;;;;;;;;;;;;;;;;;;;;;;;;/h3-10H,1-2H2,(H,12,13,14)(H,15,16,17)(H,18,19,20)(H,21,22,23)(H,24,25,26)(H,27,28,29)(H,30,31,32)(H,33,34,35);;;;;;;;;16*1H2/q;8*+3;;;;;;;;;;;;;;;;/p-24/t3-,4-,5+,6-,7+,8+,9+,10-,11-;;;;;;;;;;;;;;;;;;;;;;;;/m1......................../s1
IUPAC Name
[({[(2S,3R,4S,5R,6R)-4,5-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-6-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]-2-{[(2R,3S,4S,5R)-3,4,5-tris({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxolan-2-yl]oxy}oxan-3-yl]oxy}sulfonyl)oxy]alumanediol
SMILES
O[Al](O)OS(=O)(=O)OC[[email protected]]1O[[email protected]@H](O[[email protected]]2(COS(=O)(=O)O[Al](O)O)O[[email protected]](OS(=O)(=O)O[Al](O)O)[[email protected]@H](OS(=O)(=O)O[Al](O)O)[[email protected]@H]2OS(=O)(=O)O[Al](O)O)[[email protected]](OS(=O)(=O)O[Al](O)O)[[email protected]@H](OS(=O)(=O)O[Al](O)O)[[email protected]@H]1OS(=O)(=O)O[Al](O)O

Pharmacology

Indication

For the short-term treatment (up to 8 weeks) of active duodenal ulcer, as well as maintenance therapy for duodenal ulcer patients at reduced dosage (1 gram twice a day) after healing of acute ulcers. Also used for the short-term treatment of gastric ulcer.

Structured Indications
Pharmacodynamics

Sucralfate is a prescription medication used to treat peptic ulcers. The current clinical uses of sucralfate are limited. It is effective for the healing of duodenal ulcers, but it is not frequently used for this since more effective drugs (e.g. proton pump inhibitors) have been developed. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. Chemically, sucralfate is a complex of the disaccharide sugar, sucrose, combined with sulfate and aluminum. In acidic solutions (e.g. gastric acid) it forms a thick paste that has a strong negative charge.

Mechanism of action

Although sucralfate's mechanism is not entirely understood, there are several factors that most likely contribute to its action. Sucralfate, with its strong negative charge, binds to exposed positively-charged proteins at the base of ulcers. In this way, it coats the ulcer and forms a physical barrier that protects the ulcer surface from further injury by acid and pepsin. It directly inhibits pepsin (an enzyme that breaks apart proteins) in the presence of stomach acid and binds bile salts coming from the liver via the bile thus protecting the stomach lining from injury caused by the bile acids. Sucralfate may increase prostaglandin production. Prostaglandins are known to protect the lining of the stomach and may also bind epithelial growth factor and fibroblast growth factor, both of which enhance the growth and repair mechanism of the stomach lining.

TargetActionsOrganism
APepsin
inhibitor
Human
AFibroblast growth factor 2
agonist
Human
APro-epidermal growth factor
inducer
Human
UFibrinogen alpha chain
antagonist
Human
UFibrinogen beta chain
antagonist
Human
UFibrinogen gamma chain
antagonist
Human
Absorption

Minimally absorbed from the gastrointestinal tract (up to 5% of the disaccharide component and less than 0.02% of aluminum).

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.

Half life

Not known.

Clearance
Not Available
Toxicity

Acute oral toxicity (LD50) in mice is >8000 mg/kg. There is limited experience in humans with overdosage of sucralfate. Sucralfate is only minimally absorbed from the gastrointestinal tract and thus risks associated with acute overdosage should be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONESucralfate can cause a decrease in the absorption of 2-HYDROXY-1,4-NAPHTHOQUINONE resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
2-mercaptobenzothiazoleSucralfate can cause a decrease in the absorption of 2-mercaptobenzothiazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
AcenocoumarolSucralfate may decrease the anticoagulant activities of Acenocoumarol.Approved
AmorolfineSucralfate can cause a decrease in the absorption of Amorolfine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Amphotericin BSucralfate can cause a decrease in the absorption of Amphotericin B resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AnidulafunginSucralfate can cause a decrease in the absorption of Anidulafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ArtemetherSucralfate can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bafilomycin A1Sucralfate can cause a decrease in the absorption of Bafilomycin A1 resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Benzoic AcidSucralfate can cause a decrease in the absorption of Benzoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BifonazoleSucralfate can cause a decrease in the absorption of Bifonazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Brefeldin ASucralfate can cause a decrease in the absorption of Brefeldin A resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ButenafineSucralfate can cause a decrease in the absorption of Butenafine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ButoconazoleSucralfate can cause a decrease in the absorption of Butoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CalcidiolThe serum concentration of Sucralfate can be increased when it is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe serum concentration of Sucralfate can be increased when it is combined with Calcipotriol.Approved
CandicidinSucralfate can cause a decrease in the absorption of Candicidin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Capric acidSucralfate can cause a decrease in the absorption of Capric acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CaspofunginSucralfate can cause a decrease in the absorption of Caspofungin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CeruleninSucralfate can cause a decrease in the absorption of Cerulenin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ChloroxineSucralfate can cause a decrease in the absorption of Chloroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ChlortetracyclineSucralfate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Cholic AcidSucralfate can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclopiroxSucralfate can cause a decrease in the absorption of Ciclopirox resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Sucralfate.Approved, Investigational, Withdrawn
ClorindioneSucralfate may decrease the anticoagulant activities of Clorindione.Experimental
ClotrimazoleSucralfate can cause a decrease in the absorption of Clotrimazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CordycepinSucralfate can cause a decrease in the absorption of Cordycepin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
CyclosporineSucralfate can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DemeclocyclineSucralfate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DichloropheneSucralfate can cause a decrease in the absorption of Dichlorophene resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
DicoumarolSucralfate may decrease the anticoagulant activities of Dicoumarol.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Sucralfate.Approved
DihydrotachysterolThe serum concentration of Sucralfate can be increased when it is combined with Dihydrotachysterol.Approved
DiphenadioneSucralfate may decrease the anticoagulant activities of Diphenadione.Experimental
Dipotassium phosphateSucralfate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Sucralfate.Approved
DoxercalciferolThe serum concentration of Sucralfate can be increased when it is combined with Doxercalciferol.Approved
DoxycyclineSucralfate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EconazoleSucralfate can cause a decrease in the absorption of Econazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EfinaconazoleSucralfate can cause a decrease in the absorption of Efinaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Sucralfate.Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Sucralfate.Approved, Investigational
ErgocalciferolThe serum concentration of Sucralfate can be increased when it is combined with Ergocalciferol.Approved, Nutraceutical
Ethyl biscoumacetateSucralfate may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FenticonazoleSucralfate can cause a decrease in the absorption of Fenticonazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Sucralfate.Approved
FluconazoleSucralfate can cause a decrease in the absorption of Fluconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlucytosineSucralfate can cause a decrease in the absorption of Flucytosine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluindioneSucralfate may decrease the anticoagulant activities of Fluindione.Investigational
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Sucralfate.Withdrawn
FlutrimazoleSucralfate can cause a decrease in the absorption of Flutrimazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FurosemideThe serum concentration of Furosemide can be decreased when it is combined with Sucralfate.Approved, Vet Approved
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Sucralfate.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Sucralfate.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Sucralfate.Approved, Investigational
GlyphosateSucralfate can cause a decrease in the absorption of Glyphosate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Sucralfate.Investigational, Withdrawn
GriseofulvinSucralfate can cause a decrease in the absorption of Griseofulvin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
HachimycinSucralfate can cause a decrease in the absorption of Hachimycin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
HaloproginSucralfate can cause a decrease in the absorption of Haloprogin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
HexetidineSucralfate can cause a decrease in the absorption of Hexetidine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IsoconazoleSucralfate can cause a decrease in the absorption of Isoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ItraconazoleSucralfate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
KetoconazoleSucralfate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Sucralfate.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Sucralfate.Approved
MepartricinSucralfate can cause a decrease in the absorption of Mepartricin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MevastatinSucralfate can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MicafunginSucralfate can cause a decrease in the absorption of Micafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MiconazoleSucralfate can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MiltefosineSucralfate can cause a decrease in the absorption of Miltefosine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MinocyclineSucralfate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MonensinSucralfate can cause a decrease in the absorption of Monensin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
MyxothiazolSucralfate can cause a decrease in the absorption of Myxothiazol resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
NaftifineSucralfate can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Sucralfate.Approved, Investigational
NatamycinSucralfate can cause a decrease in the absorption of Natamycin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Sucralfate.Investigational
NifuratelSucralfate can cause a decrease in the absorption of Nifuratel resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Nikkomycin ZSucralfate can cause a decrease in the absorption of Nikkomycin Z resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NitroxolineSucralfate can cause a decrease in the absorption of Nitroxoline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Sucralfate.Approved
NystatinSucralfate can cause a decrease in the absorption of Nystatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
OmoconazoleSucralfate can cause a decrease in the absorption of Omoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxiconazoleSucralfate can cause a decrease in the absorption of Oxiconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oxolinic acidThe serum concentration of Oxolinic acid can be decreased when it is combined with Sucralfate.Experimental
pafuramidineSucralfate can cause a decrease in the absorption of pafuramidine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
ParicalcitolThe serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.Approved, Investigational
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Sucralfate.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Sucralfate.Approved
PentamidineSucralfate can cause a decrease in the absorption of Pentamidine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhenindioneSucralfate may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonSucralfate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
Pipemidic acidThe serum concentration of Pipemidic acid can be decreased when it is combined with Sucralfate.Experimental
Piromidic acidThe serum concentration of Piromidic acid can be decreased when it is combined with Sucralfate.Experimental
PosaconazoleSucralfate can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Sucralfate.Investigational
PyrrolnitrinSucralfate can cause a decrease in the absorption of Pyrrolnitrin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Sucralfate.Approved
RadicicolSucralfate can cause a decrease in the absorption of Radicicol resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Sucralfate.Approved, Investigational
RufloxacinThe serum concentration of Rufloxacin can be decreased when it is combined with Sucralfate.Experimental
Salicylhydroxamic AcidSucralfate can cause a decrease in the absorption of Salicylhydroxamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Salicylic acidSucralfate can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
SertaconazoleSucralfate can cause a decrease in the absorption of Sertaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SinefunginSucralfate can cause a decrease in the absorption of Sinefungin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SirolimusSucralfate can cause a decrease in the absorption of Sirolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SitafloxacinThe serum concentration of Sitafloxacin can be decreased when it is combined with Sucralfate.Experimental, Investigational
Sodium glycerophosphateSucralfate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateSucralfate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Sucralfate.Approved, Investigational
SulconazoleSucralfate can cause a decrease in the absorption of Sulconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Sucralfate.Approved, Investigational
TavaboroleSucralfate can cause a decrease in the absorption of Tavaborole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Sucralfate.Withdrawn
TerbinafineSucralfate can cause a decrease in the absorption of Terbinafine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
TerconazoleSucralfate can cause a decrease in the absorption of Terconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThymolSucralfate can cause a decrease in the absorption of Thymol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TioclomarolSucralfate may decrease the anticoagulant activities of Tioclomarol.Experimental
TioconazoleSucralfate can cause a decrease in the absorption of Tioconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TolciclateSucralfate can cause a decrease in the absorption of Tolciclate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
TolnaftateSucralfate can cause a decrease in the absorption of Tolnaftate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrimetrexateSucralfate can cause a decrease in the absorption of Trimetrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Sucralfate.Approved, Investigational, Withdrawn
VoriconazoleSucralfate can cause a decrease in the absorption of Voriconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
WarfarinSucralfate may decrease the anticoagulant activities of Warfarin.Approved
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

References

Synthesis Reference

Nick V. Lazaridis, Moo K. Park, Yousry Sayed, "Method for preparing high potency sucralfate." U.S. Patent US4990610, issued March, 1973.

US4990610
General References
  1. Rees WD: Mechanisms of gastroduodenal protection by sucralfate. Am J Med. 1991 Aug 8;91(2A):58S-63S. [PubMed:1715673]
External Links
Human Metabolome Database
HMDB14508
KEGG Compound
C07314
PubChem Compound
70789197
PubChem Substance
46508862
ChemSpider
26329506
ChEMBL
CHEMBL2029132
PharmGKB
PA451524
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Sucralfate
ATC Codes
A02BX02 — Sucralfate
AHFS Codes
  • 56:28.32 — Protectants
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentOesophagitis, Eosinophilic1
2Enrolling by InvitationSupportive CareGingivostomatitis / Hand, Foot, and Mouth Disease / Herpangina1
3CompletedSupportive CareHead and Neck Carcinoma / Mucositis1
4CompletedTreatmentAntimicrobial Drug Susceptibility Pattern / Etiological Organisms / Stress Ulcer Prophylaxis / Ventilator-associated Bacterial Pneumonia1
4CompletedTreatmentChronic Erosive Gastritis1
4CompletedTreatmentChronic Radiation Proctitis1
Not AvailableRecruitingDiagnosticNon-erosive Reflux Disease (NERD) / Reflux, Gastroesophageal1
Not AvailableWithdrawnDiagnosticGastroesophageal Reflux Disease / Indigestion / Non Erosive Reflux Disease1

Pharmacoeconomics

Manufacturers
  • Axcan pharma us inc
  • Nostrum laboratories inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
SuspensionOral1 g/10mL
TabletOral1000 mg
TabletOral1 g/1
SuspensionOral100 mg
SuspensionOral1 g
TabletOral1 g
Prices
Unit descriptionCostUnit
Sucralfate 1 gm/10ml Suspension 10ml Cup13.99USD cup
Carafate 1 gm tablet1.45USD tablet
Sucralfate 1 gm tablet0.72USD tablet
Sucralfate powder0.6USD g
Sulcrate 1 g Tablet0.59USD tablet
Apo-Sucralfate 1 g Tablet0.31USD tablet
Novo-Sucralate 1 g Tablet0.31USD tablet
Nu-Sucralfate 1 g Tablet0.31USD tablet
Pms-Sucralfate 1 g Tablet0.31USD tablet
Carafate 1 gm/10ml Suspension0.24USD ml
Sulcrate Suspension Plus 200 mg/ml Suspension0.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble in cold waterNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.714 mg/mLALOGPS
logP0.98ALOGPS
logP-5.6ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count35ChemAxon
Hydrogen Donor Count16ChemAxon
Polar Surface Area772.17 Å2ChemAxon
Rotatable Bond Count36ChemAxon
Refractivity175.09 m3·mol-1ChemAxon
Polarizability105.22 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7959
Blood Brain Barrier+0.8803
Caco-2 permeable-0.6433
P-glycoprotein substrateNon-substrate0.8087
P-glycoprotein inhibitor INon-inhibitor0.5656
P-glycoprotein inhibitor IINon-inhibitor0.986
Renal organic cation transporterNon-inhibitor0.8471
CYP450 2C9 substrateNon-substrate0.8611
CYP450 2D6 substrateNon-substrate0.8256
CYP450 3A4 substrateNon-substrate0.6233
CYP450 1A2 substrateNon-inhibitor0.772
CYP450 2C9 inhibitorNon-inhibitor0.8211
CYP450 2D6 inhibitorNon-inhibitor0.8865
CYP450 2C19 inhibitorNon-inhibitor0.7869
CYP450 3A4 inhibitorNon-inhibitor0.9828
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.5805
CarcinogenicityNon-carcinogens0.5356
BiodegradationNot ready biodegradable0.8432
Rat acute toxicity2.4219 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7937
hERG inhibition (predictor II)Non-inhibitor0.8793
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as disaccharide sulfates. These are disaccharides carrying one or more sulfate group on a sugar unit.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Disaccharide sulfates
Alternative Parents
O-glycosyl compounds / Ketals / Oxanes / Alkyl sulfates / Tetrahydrofurans / Oxacyclic compounds / Organic metal salts / Organic oxides / Hydrocarbon derivatives
Substituents
Disaccharide sulfate / Glycosyl compound / O-glycosyl compound / Ketal / Oxane / Alkyl sulfate / Organic sulfuric acid or derivatives / Tetrahydrofuran / Organic metal salt / Oxacycle
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

1. Pepsin
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Jensen SL, Funch Jensen P: Role of sucralfate in peptic disease. Dig Dis. 1992;10(3):153-61. [PubMed:1611711]
  2. Hollander D, Tarnawski A: The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1-5. [PubMed:2190304]
  3. Peterson WL: Pathogenesis and therapy of peptic ulcer disease. J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. [PubMed:1978840]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name
FGF2
Uniprot ID
P09038
Uniprot Name
Fibroblast growth factor 2
Molecular Weight
30769.715 Da
References
  1. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  2. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  3. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M: Growth factors: new 'endogenous drugs' for ulcer healing. Scand J Gastroenterol Suppl. 1995;210:15-8. [PubMed:8578198]
  4. Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [PubMed:1970337]
  5. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PubMed:7948825]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Transmembrane receptor protein tyrosine kinase activator activity
Specific Function
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in ...
Gene Name
EGF
Uniprot ID
P01133
Uniprot Name
Pro-epidermal growth factor
Molecular Weight
133993.12 Da
References
  1. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  2. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  3. Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [PubMed:1970337]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Structural molecule activity
Specific Function
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function ...
Gene Name
FGA
Uniprot ID
P02671
Uniprot Name
Fibrinogen alpha chain
Molecular Weight
94972.455 Da
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Structural molecule activity
Specific Function
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function...
Gene Name
FGB
Uniprot ID
P02675
Uniprot Name
Fibrinogen beta chain
Molecular Weight
55927.9 Da
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Structural molecule activity
Specific Function
Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. I...
Gene Name
FGG
Uniprot ID
P02679
Uniprot Name
Fibrinogen gamma chain
Molecular Weight
51511.29 Da
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34